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Abstract
Background: CC chemokine receptor proteins (CCR1 through CCR10) are seven-transmembrane G-protein coupled 
receptors whose signaling pathways are known for their important roles coordinating immune system responses 
through targeted trafficking of white blood cells. In addition, some of these receptors have been identified as fusion 
proteins for viral pathogens: for example, HIV-1 strains utilize CCR5, CCR2 and CCR3 proteins to obtain cellular entry in 
humans. The extracellular domains of these receptor proteins are involved in ligand-binding specificity as well as 
pathogen recognition interactions.
In mammals, the majority of chemokine receptor genes are clustered together; in humans, seven of the ten genes are
clustered in the 3p21-24 chromosome region. Gene conversion events, or exchange of DNA sequence between genes,
have been reported in chemokine receptor paralogs in various mammalian lineages, especially between the
cytogenetically closely located pairs CCR2/5 and CCR1/3. Datasets of mammalian orthologs for each gene were
analyzed separately to minimize the potential confounding impact of analyzing highly similar sequences resulting
from gene conversion events.
Molecular evolution approaches and the software package Phylogenetic Analyses by Maximum Likelihood (PAML)
were utilized to investigate the signature of selection that has acted on the mammalian CC chemokine receptor (CCR)
gene family. The results of neutral vs. adaptive evolution (positive selection) hypothesis testing using Site Models are
reported. In general, positive selection is defined by a ratio of nonsynonymous/synonymous nucleotide changes (dN/
dS, or ω) >1.
Results: Of the ten mammalian CC motif chemokine receptor sequence datasets analyzed, only CCR2 and CCR3 
contain amino acid codon sites that exhibit evidence of positive selection using site based hypothesis testing in PAML. 
Nineteen of the twenty codon sites putatively indentified as likely to be under positive selection code for amino acid 
residues located in extracellular domains of the receptor protein products.
Conclusions: These results suggest that amino acid residues present in intracellular and membrane-bound domains 
are more selectively constrained for functional signal transduction and homo- or heterodimerization, whereas amino 
acid residues in extracellular domains of these receptor proteins evolve more quickly, perhaps due to heightened 
selective pressure resulting from ligand-binding and pathogen interactions of extracellular domains.
Background
Chemotactic or chemoattractant cytokine (chemokine)
proteins are a unique division of cytokines characterized
by their roles in cell signaling through the use of het-
erotrimeric GTP-binding (G protein-coupled) 7-trans-
membrane receptors [1-3]. Chemokines are the largest
family of cytokines [4]. Currently, 42 ligand molecules
and 19 receptors belong to the chemokine superfamily of
cytokines [5]. Within the chemokine superfamily, protein
sub-families are distinguished by differences in amino
acid sequence motif of four conserved cysteines residues
[6]. Chemokine ligands in the CC (β) sub-family have two
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adjacent cysteines that are both involved in intra-chain
disulfide bridges [7]. There are ten CC motif chemokine
receptors (CCR1 through CCR10) that bind these ligands
with differing ligand binding specificity [2,5].
Chemokines, in conjunction with adhesion molecules,
recruit specific subpopulations of leukocytes by activat-
ing various receptors and initiating signaling through G
protein-coupled pathways [8,9]. The signaling of
chemokines through their receptors affect various cellu-
lar outcomes including leukocyte trafficking, gene tran-
scription, degranulation of immune response cells,
mitogenic processes, and apoptosis [2,5,6,8]. Chemokines
generally act as secondary pro-inflammatory mediators
that are induced by primary pro-inflammatory mediators
[1].
Nucleotide mutations in the open reading frame coding
for chemokine receptors can have a dramatic effect on
receptor activity or little effect, depending on the location
of the substitution and the nature of the amino acid
replacement: amino acid substitutions resulting in altera-
tions at key ligand binding extracellular domains or intra-
cellular G-protein coupled domains in particular are
known to result in disrupted or abnormal receptor activ-
ity [4]. Deficient signal transduction can result in
increased susceptibility to infectious diseases as a result
of the lack of a robust signaling response to pathogenic
infection [10-16]. Mutations in the regulatory nucleotide
sequence of chemokine receptors can also result in
changes in gene expression and subsequent protein activ-
ity [17,18].
In addition to their roles as pro-inflammatory agents in
innate immune response through binding of endogenous
ligands and subsequent receptor activation, some
chemokine receptors have been co-opted to act as recep-
tors or fusion proteins for a number of pathogens includ-
ing HIV-1 strains [19,20], protozoan parasites
Plasmodium knowlesi and P. vivax [21], and Epstein-Barr
virus [22]; herpesviruses mimic host chemokine recep-
tors to elude host immune responses [23]. Mutations in
regulatory or coding sequences for chemokine receptors
that are used as pathogen fusion proteins can alter host-
pathogen interactions: amino acid substitutions in extra-
cellular domains can prevent recognition by the pathogen
or interfere with the pathogen's ability to utilize the
receptor as a gateway into the cell. Genetic markers asso-
ciated with disease resistance have been found in regula-
tory and coding sequences of chemokine receptors [24-
29].
Because of their critical role in signaling immune
responses, chemokine receptors are subjects of intense
selection to accommodate signaling molecules, and are
expected to experience purifying selection to maintain
conformation and functionality of ligand binding and sig-
naling [30]. However, because of their role as targets of
pathogen entry, chemokine receptors are also expected to
experience positive selection pressure in response to
viral/pathogen hijacking [31]. Loci that are involved in
responses to a variety of pathogens may experience bal-
ancing selection as a result of diverging selection pres-
sures acting simultaneously on genes which may result in
the maintenance of polymorphism [32]. Given this appar-
ent evolutionary tension, it is of interest to investigate the
signature of selection on this subfamily of chemokine
receptors.
Results
Hypothesis Testing with Site Models
This paper presents the results of PAML hypothesis test-
ing on chemokine receptor sequence datasets with "Site"
models only [33,34]. These models analyze sequence data
at the level of the codon, and test whether a hypothesis
(model) that allows for positive selection (dN/dS > 1 for
some codons) is better fit to the data when compared to a
null neutral hypothesis (model), determined through per-
forming a likelihood ratio test between the likelihood
scores of the null neutral and selection models. Each set
of orthologous gene sequences was analyzed indepen-
dently of one another such that only CCR1  gene
sequences were included in the first data set, only CCR2
gene sequences were included in the second data set, and
so on for each of the ten CCR genes (i.e., paralogous
genes were not in the same data set).
When testing the hypothesis that some codon sites
within chemokine receptor coding sequences have expe-
rienced positive selection pressure, significant results
were obtained for some codons within the genes CCR2
and CCR3 (Table 1). For CCR2, the comparison between
a null neutral site model which does not allow positive
selection (M1a) and a selection site model (M2a) yielded
a likelihood ratio test statistic of 5.45, which did not allow
for rejection of the null hypothesis of neutral selection.
However, the comparison between an additional pair of
site models, M7 (null, neutral) and M8 (selection) for
CCR2 yielded a likelihood test ratio statistic of 15.22, sig-
nificant at p = 0.001, and a proportion of sites (0.02430,
2.4%) with ω = 2.83526. The analysis for CCR2 had a total
of 380 amino acid sites, and nine amino acid sites were
identified as sites of positive selection (Table 2) using
Bayes empirical Bayes (BEB) analysis [35]. One of the
nine amino acid sites identified under positive selection
had strong support with BEB posterior probability >95%.
Eight of the nine amino acids identified as having experi-
enced positive selection in the coding sequence of CCR2
are located in extracellular domains of the protein; one
positively selected amino acid residue is located in the
second transmembrane domain, near the transmem-
brane/extracellular boundary (Figure 1).Metzger and Thomas BMC Evolutionary Biology 2010, 10:139
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For hypothesis testing of site models with CCR3 gene
sequences, the comparison of M1a (neutral) vs. M2a
(selection) site models led to rejection of the null, neutral
hypothesis in favor of selection with a likelihood test ratio
statistic of 19.84, significant at p = 0.001, with a propor-
tion of sites (0.01346 1%), and ω = 5.44115, indicating
positive selection for those codon sites (Table 1). Five
specific codon sites within the coding sequence were
reported under positive selection with a BEB analysis fol-
lowing site testing: one site had strong support with BEB
posterior probability greater than 95%, and one site had
very strong support with BEB posterior probability
greater than 99% (Table 2). A significant result was also
obtained in the comparison of the second set of site mod-
els, M7 versus M8, with a test statistic of 22.3, significant
at p = 0.001, with a proportion of sites (0.01637, ~1.6%)
having a dN/dS value of 5.44 (Table 1). The analysis for
CCR3 included 361 amino acid sites, and eleven specific
amino acid sites were reported under positive selection
with a BEB analysis following the site test. Three of these
positively selected amino acid sites had posterior proba-
bilities greater than 95%, one site had a posterior proba-
bility greater than 99% (Table 2). All of the positively
selected sites identified for CCR3 in this analysis were
located in extracellular domains of the receptor protein
(Figure 2). A summary of results (significant and non sig-
nificant) for all site model tests is presented in Additional
File 1.
Discussion
None of the ten CC motif chemokine receptors has a sig-
nature of positive selection as indicated by an ω value
(ratio of nonsynonymous substitutions/synonymous sub-
stitutions, dN/dS) greater than one averaged over all
codons as determined by hypothesis testing using branch
models in PAML (unpublished results). Site tests, which
analyze the sequence at the unit of the codon, revealed a
proportion of codon sites that display evidence of positive
selection (ω > 1) within the coding sequences of CCR2
and CCR3. The results obtained under the two sets of site
models (M1a vs. M2a and M7 vs. M8) differ in some
aspects; for example, the more conservative M1a vs. M2a
comparison did not reveal statistically significant results
for CCR2 while the M7 vs. M8 comparison did reveal sig-
nificant differences, allowing for the identification of pos-
itively selected sites. For CCR3, while both M1a vs. M2a
Table 1: Model Parameter Estimates, dN/dS Ratios, Log Likelihood Values and Test Statistics for PAML Site Models.
Gene Model Parameters dN/dS p l 2Δl
CCR2 M7: Neutral, 
beta
p = 0.33949, 
q = 1.05276
0.2417 2 -4931.71
M8: Selection, 
beta + ω
p0 = 0.97570, 
p = 0.45144
0.2728 4 -4924.10 M7 vs. M8: 
15.22***
q = 1.67059, 
(p1 = 0.02430)
ω = 2.83526
CCR3 M1a: Nearly 
Neutral
ω0 = 0.07487, 
ω1 = 1.00
0.4314 2 -5536.21
p0 = 0.61460, 
(p1 = 0.38540)
M2a: Selection ω0 = 0.07422, 
ω1 = 1.00
0.5014 4 -5526.29 M1a vs. M2a: 
19.84***
ω2 = 5.44115, 
p0 = 0.60315
p1 = 0.38339, 
(p2 = 0.01346)
CCR3 M7: Neutral, 
beta
p = 0.22415, 
q = 0.35810
0.3850 2 -5534.05
M8: Selection, 
beta + ω
p0 = 0.98363, 
p = 0.23871
0.2662 4 -5522.90 M7 vs. M8: 
22.30***
q = 0.3298, 
(p1 = 0.01637)
ω = 4.50735
The test statistic 2Δl is compared to a χ2 distribution with 2 degrees of freedom, critical values 5.99, 9.21, and 13.82 at 5%, 1%, and 0.1% 
significance, respectively. Significant results are indicated by asterisks. Values for non-significant comparisons are presented in Additional File 
1.Metzger and Thomas BMC Evolutionary Biology 2010, 10:139
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and M7 vs. M8 were both statistically significant compar-
isons, the comparison between M7 and M8 identified the
same five codon sites that had been identified under M1a
vs. M2a comparison as well as additional positively
selected sites that were not identified in the M1a vs. M2a
comparison. The differences in the results obtained using
different models reflect that the M1a vs. M2a comparison
is a more conservative test which may fail to detect posi-
tively selected sites identified by the less conservative M7
vs. M8 comparison.
It is interesting to note that in the results obtained for
CCR2 and CCR3, nineteen out of the twenty amino acid
sites that are identified as having experienced positive
selection are located in the extracellular domains of the
chemokine receptor proteins, suggesting that nonsynony-
mous substitutions are occurring, and more often being
selected for, in the ligand binding and pathogen interac-
tion regions of the receptors. Previous studies on CCR2,
CCR3 and other CC chemokine receptors have identified
the amine-terminus and extracellular domains as being
important for both the endogenous ligand-binding func-
tions [36-42] as well as for binding efficacy for pathogens
in situations where these receptors have been co-opted as
fusion proteins [24,43-45]. These previous results cou-
pled with the findings presented here point to the extra-
cellular domains of CC chemokine receptor proteins
being especially relevant to studies of the evolution of
structure and function of receptors for endogenous
ligand binding ability and as targets of pathogen interac-
tion.
Recombination or gene conversion between paralogs in
the chemokine receptor family has been investigated and
described, particularly for CCR2/5 conversion in several
orders of mammals [31,46-50]. Conversion events
Table 2: Positively Selected Sites Under Different PAML Site Models Using Bayes Empirical Bayes Analysis.
Gene Model Codon Domain Amino Acid Posterior 
Probability
Post Mean +- 
SE for ω
CCR2 M8: Selection, 
beta+ ω
16 EC S 0.632 1.536 +- 0.783
23 EC F 0.795 1.796 +- 0.781
43 EC Q 0.0916 1.977 +- 0.729
95 MB L 0.795 1.807 +- 0.810
115 EC L 0.623 1.535 +- 0.825
183 EC K 0.0926 1.986 +- 0.720
187 EC V 0.705 1.678 +- 0.831
196 EC R 0.961* 2.028 +- 0.691
197 EC G 0.862 1.910 +- 0.771
CCR3 M2a: Selection 4 EC S 0.638 3.459 +- 2.147
5 EC L 0.988* 4.851 +- 1.496
20 EC V 0.998** 4.881 +- 1.453
179 EC T 0.919 4.581+- 1.731
181 EC T 0.878 4.378 +- 1.807
CCR3 M8: Selection, 
beta+ ω
4 EC S 0.824 2.296 +- 0.904
5 EC L 0.988* 2.590 +- 0.683
20 EC V 0.997** 2.603 +- 0.667
31 EC A 0.549 1.734 +- 0.921
95 EC R 0.681 2.000 +- 0.947
96 EC G 0.598 1.830 +- 0.940
104 EC G 0.863 2.347 +- 0.833
177 EC L 0.528 1.688 +- 0.902
179 EC E 0.550 1.748 +- 0.967
181 EC T 0.962* 2.545 +- 0.729
Asterisks indicate posterior probability P > 95% (*) and P > 99%(**). For codon position, the amino acid number is given followed by an 
abbreviation for the domain in which the amino acid is found: EC = extracellular, MB = membrane bound, IC = intracellular.Metzger and Thomas BMC Evolutionary Biology 2010, 10:139
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between CCR1/3 in rodents have also been reported [31].
These conversion events have primarily involved trans-
membrane regions, but some conversion events have
occurred more extensively over CCR gene sequences and
have impacted extracellular domains; for example the
first extracellular loop of CCR5 converted by recombina-
tion with CCR2 in Mus [31], extracellular loop 2 of CCR5
converted by recombination with CCR2  in  Homo  and
Oryctolagus [31,46,50], and extracellular loop 3 of CCR3
converted by recombination with CCR1 in Mus [31].
Analysis of sequences that have undergone gene con-
version can lead to higher rate of false-positives when
using maximum likelihood methods to detect positive
selection, particularly in small data sets with only a few
sequences, although the rate of false positives is only
increased moderately [51]. To minimize the impact of
gene conversion events on the results of this study and as
an alternative to eliminating sequences or parts of
sequences that have undergone conversion events, each
set of orthologous genes was analyzed independently of
one another such that highly similar sequences resulting
from gene conversion events within a species involving
paralogous genes were not included in the same analysis,
but rather were analyzed independently in separate data
sets (e.g., only CCR1  gene sequences were analyzed
together in one data set; CCR2 gene sequences were ana-
lyzed in a separate data set, and so on). In addition, a
Bayes Empirical Bayes (BEB) analysis was used rather
than Naïve Empirical Bayes (NEB) to identify putative
codons under positive selection as NEB is less conserva-
tive and can be more prone to error in smaller data sets
[34,35] whereas BEB produces a low rate of false-posi-
tives with sequences that have experienced gene conver-
sion [51].
Both of the genes containing positively selected codon
sites (CCR2  and  CCR3)  have been reported to have
undergone gene conversion events as discussed above;
however, in the case of CCR2, gene conversion events
have led to the conversion of CCR5 by CCR2, whereas in
the case of CCR3, it is CCR3 that has been converted by
CCR1. The results presented here, in which only one gene
of a gene conversion pair displays evidence of positive
selection through hypothesis testing, indicate that inde-
pendent analyses of sequences that have undergone gene
conversion may mitigate the detection of false-positives
due to gene conversion.
Conclusions
Site tests, which analyze genetic sequences at the unit of
the codon, revealed a proportion of codon sites that dis-
Figure 1 Location of CCR2 Positively Selected Codon Sites in Extracellular Receptor Protein Domains. Stars indicate the location of positively 
selected sites in CCR2: Green stars indicate positively selected sites with a Bayes Empirical Bayes posterior probability ≤ 95%, blue stars indicate posi-
tively selected sites with posterior probability ≥95%. Diagram created with RbDe online software application [62].Metzger and Thomas BMC Evolutionary Biology 2010, 10:139
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play evidence of positive selection (ω > 1) within the cod-
ing sequences of mammalian CC motif chemokine
receptor genes CCR2 and CCR3. Nineteen of the twenty
amino acid sites identified as having experienced positive
selection are located in extracellular domains of the
chemokine receptor proteins CCR2 and CCR3. These
results suggest that amino acid residues present in intrac-
ellular and membrane-bound domains of mammalian CC
motif chemokine receptor proteins are more selectively
constrained, whereas amino acid residues in extracellular
domains of these receptor proteins evolve more quickly,
perhaps due to heightened selective pressure resulting
from ligand-binding and pathogen interactions of extra-
cellular domains.
Methods
Genomic coding sequences for CCRs from a number of
placental mammals were obtained through searches of
the online database NCBI Gene [52]. Taxa included in the
data set were chosen using the recently updated placental
mammal phylogeny [53] and the online software applica-
tion TimeTree [54,55] to estimate divergence times
between taxa (estimates given for nuclear genes were
used). For PAML analyses, taxa that have diverged more
than ~100 MYA may lead to decreased analytical power
due to highly divergent sequences, difficulty in sequence
alignment, and saturation of substitutions [56-58]; there-
fore, only taxa that have diverged less than 100 MYA were
included in the data set.
For genes that displayed alternative splicing patterns,
the presumed ancestral isoform sequence was identified
through alignment methods and included in the dataset
while the alternative isoforms were not. For CCR2, the
human isoform that localizes to the plasma membrane
was included in the CCR2 dataset, while the cytoplasmic
variant was not. Species and GenBank accession numbers
Figure 2 Location of CCR3 Positively Selected Codon Sites in Extracellular Receptor Protein Domains. Stars indicate the location of positively 
selected sites in CCR3: Green stars indicate positively sites with a Bayes Empirical Bayes posterior probability ≤ 95%, blue stars indicate positively sites 
with posterior probability ≥95%, red stars indicate sites under positive selection with posterior probability of ≥99%. Diagram created with RbDe online 
software application [62].Metzger and Thomas BMC Evolutionary Biology 2010, 10:139
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for sequences used in the analyses are listed in Additional
File 2.
Nucleotide alignments of chemokine receptor
sequences were generated using amino acid sequence
alignments and the software program TranAlign [59].
The output from TranAlign was converted to Nexus/
PAUP format and submitted to the software program
ModelTest [60] for selection of the most appropriate
model of evolution for each dataset by testing the fit of 56
different evolutionary models with the data set. ModelT-
est uses both hierarchical likelihood ratio testing and
Akaike Information Criterion (AIC). The best model was
chosen based on AIC score and the number of estimated
parameters. If there was a statistically insignificant differ-
ence between two models, the model with the fewest
number of estimated parameters was chosen to introduce
the least amount of uncertainty to the evolutionary analy-
ses. Models used for analyses are summarized in Addi-
tional File 3.
Phylogenetic Analysis Using Parsimony* (PAUP*) and 
Phylogenetic Analysis by Maximum Likelihood (PAML) 
Methods
Maximum likelihood phylogenetic trees for each data set
(Additional Files 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13) were
constructed with the software package PAUP* [61]. Data
sets and maximum likelihood phylogenetic trees for each
gene were submitted to PAML CODEML version 4.1
under different models and parameters to test for adap-
tive evolution either at codon sites ("Site Model"), along
l i n e a g e s  ( " B r a n c h  M o d e l " ) ,  o r  a t  s i t e s  w i t h i n  l i n e a g e s
("Branch-Site Model") [34]. This paper presents the
results of testing the data sets described with "Site" mod-
els only.
"Site" models allow the dN/dS ratio to vary across
codons within a sequence for a lineage. Proportions of
sites within each lineage were estimated to be in different
categories: positive selection is indicated by some codons
having a dN/dS > 1. The null, neutral model does not
allow positive selection and is compared to the alternative
hypothesis in which in which positive selection is
allowed.
Two sets of site models are commonly used to test
hypotheses of selection, and have been used here: M1a vs.
M2a and M7 vs. M8. In the first set of models, the model
M1a: Nearly Neutral allows 2 categories of codon sites in
p0, and p1 proportions, with ω0 < 1, and ω1 = 1, whereas
the model M2a: Selection allows an additional category of
codons (p2) with ω2 > 1, indicating positive selection. The
second set of site models compared is M7 and M8, in
which M7 specifies a neutral model with dN/dS ratios
across a continuous beta distribution with estimated
parameters p and q of the beta distribution, and M8 spec-
ifies a similar model with an additional category for sites
that have dN/dS > 1, indicating positive selection. M7
assumes a beta distribution of ω values between 0 and 1,
and therefore does not allow any sites under positive
selection (ω > 1). The M8 model is similar to M7 in that it
also assumes a beta distribution for omega values, but
allows another category of sites in which ω > 1. The com-
parison between M7: beta and M8: beta +ω is less conser-
vative, and may indicate positive selection even when
none is detected by the M1a: M2a comparison.
The PAML settings for the null (neutral) model M1a
were model = 0, NSsites = 1, and for the alternative
(selection) model M2a were model = 0, NSsites = 2. The
PAML settings for the null model M7 were model = 0,
NSsites = 7, and for the alternative (selection) model M8
were model = 0, NSsites = 8.
The likelihood estimates for each were compared using
a hierarchical Likelihood Ratio Test (hLRT) of twice the
difference in log likelihood values of the models being
compared (2ΔlnL), with the result approximating chi-
square distribution with degrees of freedom for the test
statistic determined by the difference in estimated
parameters between the models being compared. For
both the M1a (neutral) vs. M2a (selection) and M7 (beta)
vs. M8 (beta + selection) comparisons, the null model has
two estimated parameters, while the alternative estimates
four, resulting in two degrees of freedom and chi-square
critical values of 5.99, 9.21, and 13.82 at 5%, 1%, and 0.1%
significance, respectively [34].
Additional material
Additional file 1 Supplementary Table 1: Model Parameter Estimates, 
dN/dS Ratios, Log Likelihood Values and Test Statistics for PAML Site 
Models. Summary of results for all PAML hypothesis testing using site mod-
els. Includes significant and non-significant results.
Additional file 2 Supplementary Table 2: Taxa and NCBI GenBank 
accession numbers for loci included in CC chemokine receptor data 
sets. List of species and NCBI GenBank accession numbers for sequences 
used to construct the ten datasets (for each of the ten sets of orthologous 
genes) for hypothesis testing. Species and accession numbers for each 
dataset are grouped together on the table.
Additional file 3 Supplementary Table 3: Parameters for ModelTest 
models of evolution used in PAML hypothesis testing of CC 
chemokine receptor sequences. Summary of evolutionary model param-
eters used in PAML hypothesis testing.
Additional file 4 Supplementary Figure 1: Maximum likelihood phy-
logeny of mammalian CCR1 gene sequences. A phylogeny of mamma-
lian CCR1 gene sequences. The tree was produced using PHYML with the 
GTR nucleotide model, a discrete gamma model with four categories, and a 
shape parameter of 0.6525. Bootstrapping was performed with 100 repli-
cates. Bootstrap support is indicated at nodes.
Additional file 5 Supplementary Figure 2: Maximum likelihood phy-
logeny of mammalian CCR2 gene sequences. A phylogeny of mamma-
lian CCR2 gene sequences. The tree was produced using PHYML with the 
GTR nucleotide model, a discrete gamma model with four categories, and a 
shape parameter of 0.5867. Bootstrapping was performed with 100 repli-
cates. Bootstrap support is indicated at nodes.Metzger and Thomas BMC Evolutionary Biology 2010, 10:139
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portion of invariable sites 0.5901 and an estimated shape parameter of 
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port is indicated at nodes.
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